Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug - Analyst Blog

By
A A A

Bristol-Myers Squibb Company ( BMY ) announced that it intends to seek FDA approval for its high potential immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor) for the advanced melanoma indication in previously treated patients by Sep 30, 2014. The news of the impending filing boosted Bristol-Myers' shares.

Bristol-Myers said in its press release that it will seek FDA approval for the advanced melanoma indication on the basis of positive results from a phase III study (Checkmate -037). The patients in the trial were previously treated with Bristol-Myers' marketed skin cancer drug Yervoy and with a BRAF inhibitor regimen in case they were BRAF-mutation positive. We note that Opdivo was approved in Japan earlier this month for treating patients with unresectable melanoma.

Following the Japanese approval, Opdivo became the first PD-1 immune checkpoint inhibitor to gain approval. Ono Pharmaceutical has the rights to commercialize the treatment in Japan as per a 2011 agreement with Bristol-Myers.

We note that another anti-PD-1 antibody, Merck 's ( MRK ) pembrolizumab (MK-3475), is under FDA review for treating unresectable or metastatic melanoma in patients pretreated with Yervoy. A decision is expected by Oct 28, 2014. Hence it is likely that Merck will be the first company to receive FDA approval for an anti-PD-1 therapy. The candidate is also under review in the EU.

Bristol-Myers is already seeking FDA approval for Opdivo in another oncology indication, namely, third-line squamous cell non-small cell lung cancer. The biopharmaceutical major initiated a rolling submission for the indication based on results from the 063 study. Bristol-Myers expects to complete the rolling submission by Dec 31, 2014.

Approval of Opdivo for the above indications would strengthen Bristol-Myers' position in the lucrative as well as highly sought after immuno-oncology space. We expect investor focus to remain on updates regarding the high potential Opdivo. Opdivo is also being studied in other oncology indications as well, such as, renal cell carcinoma, head and neck cancer, glioblastoma and non-Hodgkin lymphoma.

Bristol-Myers carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Biogen Idec ( BIIB ) and The Medicines Co. ( MDCO ). Both the stocks sport a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

MEDICINES CO (MDCO): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BMY , MDCO , BIIB , MRK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

91,252,153
  • $13.78 ▼ 4.31%
68,133,496
  • $12.93 ▲ 6.77%
57,268,074
  • $46.13 ▲ 2.47%
43,432,023
  • $105.22 ▲ 0.37%
40,880,685
  • $13.46 ▲ 8.90%
40,712,405
  • $98.62 ▲ 0.82%
39,776,976
  • $16.72 ▲ 0.72%
34,688,871
  • $11.16 ▲ 3.05%
As of 10/24/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com